Biotech bounced back in 2013, says report


Financial services firm EY says in its annual assessment of the global biotechnology sector that the industry is performing strongly, but needs to focus on using its R&D resources more efficiently to ‘unlock value’.

Revenues, R&D spending and companies’ ability to raise capital funding all increased in 2013 compared to 2012. But the report highlights a need for the industry to be smarter about how it spends that cash. Particularly, EY decries the high failure rate of expensive Phase III clinical trials. While this observation will not surprise anyone in the industry, the report draws on case studies from across the industry to suggest some strategies that might improve efficiency.

Chief among these is not skimping on earlier trials, and designing trials to be adaptive, so they can test multiple hypotheses and reach more definitive conclusions. Other recommendations reinforce trends that are already beginning to take hold within the pharmaceutical industry: using biomarker-based diagnostics to target products more effectively at populations where they will have greatest effect, and collaborating early and often, particularly on pre-competitive problems that affect the whole sector.


Related Content

Bounce denotes battery health

31 March 2015 Research

news image

Physical changes as battery discharges correlated with bounce

Trampolining droplets raise hopes for ice-shedding surfaces

4 November 2015 Research

news image

Mystery of bouncing droplets that apparently defy the laws of physics unravelled

Most Commented

Sweet tear sensor could ease pain of diabetes

29 June 2016 Research

news image

New non-invasive sensor could check blood glucose levels using tears

The next generation

24 June 2016 Premium contentFeature

news image

Elinor Hughes catches up with some of the latest materials and processes in photovoltaics research